Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014-2015 influenza season in Alberta, Canada

Influenza Other Respir Viruses. 2016 Nov;10(6):532-535. doi: 10.1111/irv.12415. Epub 2016 Aug 8.

Abstract

This manuscript describes the identification of an oseltamivir-resistant influenza A (H3N2) virus in a respiratory specimen collected from an immunocompromised patient in Alberta, Canada, during the 2014-2015 influenza season. Following treatment with oseltamivir, neuraminidase (NA) gene sequencing indicated the presence of an R292K mutation. Phenotypic susceptibility testing by the NA-Star assay indicated a highly reduced inhibition by oseltamivir and normal inhibition by zanamivir. The use of zanamivir following identification of the oseltamivir-resistant strain, combined with a partial immune reconstitution, was followed by a suggested decrease in the nasopharyngeal viral load in the nasopharynx and clinical improvement of the patient.

Keywords: H3N2; influenza; neuraminidase inhibitors; reduced susceptibility; resistance; sequence analysis.

Publication types

  • Case Reports

MeSH terms

  • Alberta / epidemiology
  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Drug Resistance, Viral*
  • Humans
  • Immunocompromised Host*
  • Influenza A Virus, H3N2 Subtype / drug effects*
  • Influenza A Virus, H3N2 Subtype / genetics*
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza, Human / drug therapy*
  • Influenza, Human / epidemiology
  • Influenza, Human / virology
  • Male
  • Middle Aged
  • Mutation
  • Nasopharynx / virology
  • Neuraminidase / genetics
  • Oseltamivir / pharmacology*
  • Oseltamivir / therapeutic use
  • Seasons
  • Viral Load / drug effects
  • Zanamivir / therapeutic use

Substances

  • Antiviral Agents
  • Oseltamivir
  • Neuraminidase
  • Zanamivir